Cabazitaxel; Docetaxel; Paclitaxel/Strong CYP3A4 Inducers
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
Some medicines may speed up down how quickly your liver processes your cancer medicine.
What might happen:
The amount of cancer medicine in your blood may decrease and it may not work as well.
What you should do about this interaction:
Make sure your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together or if you have taken the other medicine in the previous two weeks. Your doctor may want to change the dose of your cancer medicine.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.
1.Jevtana (cabazitaxel) US prescribing information. Sanofi-Aventis U.S. LLC March, 2014.
2.Taxotere (docetaxel) US prescribing information. Sanofi-Aventis U.S. LLC December, 2013.
3.Taxol (paclitaxel) US prescribing information. Bristol-Myers Squibb Company August, 2010.
4.Goey AK, Meijerman I, Rosing H, Marchetti S, Mergui-Roelvink M, Keessen M, Burgers JA, Beijnen JH, Schellens JH. The Effect of St John's Wort on the Pharmacokinetics of Docetaxel. Clin Pharmacokinet 2014 Jan;53(1):103-10.
5.Komoroski BJ, Parise RA, Egorin MJ, Strom SC, Venkataramanan R. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures. Clin Cancer Res 2005 Oct 1;11(19 Pt 1):6972-9.
6.Fetell MR, Grossman SA, Fisher JD, Erlanger B, Rowinsky E, Stockel J, Piantadosi S. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. J Clin Oncol 1997 Sep; 15(9):3121-8.
7.US Food and Drug Administration (FDA). Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Available at: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/D rugInteractionsLabeling/ucm093664.htm. Updated 08/05/2011.
8.This information is based on or an extract from the UW Metabolism and Transport Drug Interaction Database (DIDB) Platform, Copyright University of Washington 1999-2014..